174 related articles for article (PubMed ID: 34009487)
1. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary.
Miyagi E; Arakawa N; Sakamaki K; Yokota NR; Yamanaka T; Yamada Y; Yamaguchi S; Nagao S; Hirashima Y; Kasamatsu Y; Kato H; Mogami T; Miyagi Y; Kobayashi H
Int J Clin Oncol; 2021 Jul; 26(7):1336-1344. PubMed ID: 34009487
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
3. Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma.
Arakawa N; Miyagi E; Nomura A; Morita E; Ino Y; Ohtake N; Miyagi Y; Hirahara F; Hirano H
J Proteome Res; 2013 Oct; 12(10):4340-50. PubMed ID: 23805888
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor pathway inhibitor 2: A potential diagnostic marker for discriminating benign from malignant ovarian tumors.
Kobayashi H; Yamada Y; Kawaguchi R; Ootake N; Myoba S; Kimura F
J Obstet Gynaecol Res; 2022 Sep; 48(9):2442-2451. PubMed ID: 35778814
[TBL] [Abstract][Full Text] [Related]
5. Tissue Factor Pathway Inhibitor 2: A Novel Biomarker for Predicting Asymptomatic Venous Thromboembolism in Patients with Epithelial Ovarian Cancer.
Yamanaka S; Miyake R; Yamada Y; Kawaguchi R; Ootake N; Myoba S; Kobayashi H
Gynecol Obstet Invest; 2022; 87(2):133-140. PubMed ID: 35613543
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
Ota Y; Koizume S; Nakamura Y; Yoshihara M; Takahashi T; Sato S; Myoba S; Ohtake N; Kato H; Yokose T; Miyagi E; Miyagi Y
Oncol Rep; 2021 Mar; 45(3):1023-1032. PubMed ID: 33650653
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
8. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
Yanaranop M; Jantarateptewan N; Tiyayon J; Nakrangsee S
Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
[TBL] [Abstract][Full Text] [Related]
9. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
10. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
[TBL] [Abstract][Full Text] [Related]
13. Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer.
Li M; Tan J; Zhang Y; Ai C; Wang H; Zhang H; Jin Y; Chen Y
Abdom Radiol (NY); 2021 Jun; 46(6):2367-2375. PubMed ID: 32424610
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Accuracy and Optimal Cutoff Value of Serum HE4 to Predict Ovarian Cancer in Thai Women with Pelvic Masses.
Yanaranop M; Tiyayon J; Nakrangsee S; Thinkhamrop B
J Med Assoc Thai; 2016 Dec; 99(12):1263-71. PubMed ID: 29952496
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
[TBL] [Abstract][Full Text] [Related]
16. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
17. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
[TBL] [Abstract][Full Text] [Related]
18. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
[TBL] [Abstract][Full Text] [Related]
19. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
